Klarna plunged in premarket trading after the payments company gave full-year revenue and gross merchandise value guidance that missed expectations, according to Bloomberg.

Amylyx Pharmaceuticals extended its early-session rally to as much as 54% after saying a late-stage trial of its experimental drug met its primary endpoint for patients with low blood sugar levels following bariatric surgery. Bath & Body Works surged ahead of the opening bell after Citigroup raised its rating to buy from neutral, with analyst Paul Lejuez citing a favorable risk-reward outlook. The company is scheduled to report earnings next week.